Recursion reports Phase 2 FAP data, Sanofi option, Hassan as new chair

Recursion Pharmaceuticals reported third-quarter 2026 results on November 2, 2026, alongside updated clinical data and corporate news. The company announced further positive data from its ongoing Phase 1b/2 TUPELO trial of REC-4881, an investigational oral MEK1/2 inhibitor for familial adenomatous polyposis, presented by Lisa Boardman of Mayo Clinic at the CGA-IGC Annual Meeting in Denver.¹ After 12 weeks of REC-4881 at 4 mg once daily, 87% of patients (13 of 15) had a reduction in total polyp burden, with a 47% median reduction.¹ In the upper GI tract, 92% of patients (12 of 13) had reductions after 12 weeks, with two patients achieving reductions of at least 98%.¹ The highest-grade treatment-related adverse event was Grade 1 or 2 in 81% of patients and Grade 3 in 15%, with no Grade 4 or 5 events and no additional discontinuations since the prior cutoff.¹ Recursion said it anticipates initiating a registrational trial in the second half of 2027, pending ongoing FDA discussions.¹

For REC-1245, an oral molecular glue targeting RBM39, three partial responses per RECIST 1.1 criteria (two confirmed, one unconfirmed) occurred in heavily pretreated patients with endometrial cancer and hepatocellular carcinoma, all at doses of 45 mg once daily or higher, with a 91.7% disease control rate at those doses.¹ Preliminary dose expansion data in endometrial cancer are expected in the second half of 2027.¹

Sanofi optioned the first development candidate from its multi-program research collaboration with Recursion, adding it to Sanofi's pipeline with Phase 1 trials expected in 2027.¹ The option triggered a $10 million milestone payment, bringing total payments from Sanofi to $144 million.¹

Recursion appointed Fred Hassan as Chair of the Board effective October 31, 2026.¹

Cash runway is now expected to extend into 2029, including proceeds from the October 2026 follow-on offering, with 2026 cash operating expense guidance reiterated at less than $375 million and 2027 guidance of less than $360 million.¹